Dr. Zheng has served as CEO and a member of our board of directors since he co-founded the company in 2012. He has over 25 years of biopharmaceutical industry experience in the autoimmune disease and inflammation therapeutic areas. Prior to co-founding Connect, Dr. Zheng was Director of Immunology at Arena Pharmaceuticals where he oversaw its immunology discovery programs. Prior to serving at Arena, Dr. Zheng was a scientist and program leader at ChemoCentryx, where he led the implementation of the company’s proprietary technology platform, and the discovery of drug candidates that entered Phase 2 and Phase 3 clinical trials for autoimmune disease indications, including Crohn’s disease. Dr. Zheng was a scientist at Glycomed (acquired by Ligand Pharmaceuticals) and also conducted immunology research at Stanford University School of Medicine. Dr. Zheng is an inventor of 16 issued patents and several pending patent applications on immunology related therapeutic agents and technologies. He received his Ph.D. in Biochemistry and Molecular Biology from the University of California, Davis.
Dr. Pan is a co-founder of Connect and has served as President and Chairman of the Board of Directors since May 2012. He has over 25 years of experience in biopharmaceutical R&D, including 10 years in Europe and North America. Prior to co-founding Connect, Dr. Pan co-founded and led Crown Bioscience Inc., a U.S. venture-backed company with major operations in China (Beijing & Shanghai) providing CRO services to international biopharmaceutical companies. Prior to Crown Bioscience, Dr. Pan was the Vice President at TsingHuaYuanXing Biopharmaceutical Co. Ltd., where he played key roles for the development of several gene-based therapeutic biologics. He was involved in the development and successful marketing of several biomedical products. Dr. Pan obtained his Ph.D. in Biology from University of Sussex (U.K.) and completed postdoctoral training at the University of California at Berkeley. He holds an MBA from Tsing-Hua University.
Dr. Selwyn Ho has served as an advisor to the company since January 2020 and since January 2021 as our Chief Business Officer. He has over 20 years of consulting and biopharmaceutical experience through his own consulting firm, and in senior positions in multiple pharmaceutical organisations, leading Global, Regional and Country teams responsible for product development, product strategy, medical affairs and commercialization, resulting in the successful launches of medicines in the inflammation and immunology, ophthalmology and cardiology therapeutic areas. Most recently, he was Vice President, Head of Market Access and Vice President, Head of Strategic Marketing, at Dermira Inc., a specialty Dermatology company that was acquired by Eli Lilly in 2020. Prior to Dermira, Dr. Ho held several senior strategic and operational leadership positions at UCB S.A. in immunology (Rheumatology, Gastroenterology and Dermatology), and at Allergan, as U.K. Managing Director & Country Manager, and Head of EAME Retina Franchise. He received his medical degree (MB BS) and B.Sc. in Pharmacology from Imperial College, University of London and practiced medicine in Anaesthesiology and Intensive Care.
Mr. Hall is a Partner of FLG Partners, LLC with experience serving as CEO, Chief Operating Officer, and Chief Financial Officer for a variety of public and private companies. He has extensive global experience in finance and accounting, equity capital markets, mergers and acquisitions, venture capital/alternative investments, treasury and investment management, and strategic planning. He has raised over $2 billion in debt and equity financing during his career. Mr. Hall has an MBA in Finance from the Owen Graduate School of Management, Vanderbilt University, and an A.B. in Economics from the University of California at Davis. He is a Chartered Financial Analyst and member of the CFA Institute and the CFA Society of San Francisco.
Dr. Sun has over 20 years of experience in pharmaceutical development of biologics focused on process development, CMC, and manufacturing operations. Prior to joining Connect, Dr. Sun served as Chief Technology Officer and Vice President of Manufacturing at Autekbio Diagnostics. Prior to serving at Autekbio Diagnostics, Dr. Sun supported drug development at PERCIVIA, UCB Pharma, Shire Pharmaceuticals and DSM/Crucell JV. Dr. Sun has more than 20 publications in peer-reviewed journals and was an inventor of multiple patents in biologics and process development. He obtained his Ph.D. degree in molecular biology and biochemistry from the University of Minnesota and completed his postdoctoral training in molecular immunology at Harvard Medical School.
Dr. Li has more than 25 years of experience in clinical and medical affairs in more than a dozen therapeutic areas including gastroenterology and immunology-related fields and comprising programs from Phase 1 to Phase 3 clinical development. Her prior medical affairs experience also includes supervising medical affairs, medical-scientific liaisons, medical information, pharmacovigilance, medical affairs operations, and quality management. She received an MBBS from Beijing Medical University, an MMed in Internal Medicine from Peking Union Medical College, and an MBA from Beijing International MBA at Peking University (BiMBA).
Dr. Yuelie Lu has served as Vice President, Pharmaceutical Sciences, responsible for the overall company’s small molecule CMC operations since March 2021. He has over 25 years of experience in small molecule drug development and commercialization in a range of therapeutic areas such as oncology and cardiovascular & metabolic disorders. Prior to joining Connect, Dr. Lu served in positions of increasing responsibility at a variety of biopharmaceutical companies such as Pharmacyclics/AbbVie and Amgen. He is the recipient of the American Chemical Society’s 2019 Heroes of Chemistry Award for his outstanding contribution on development and commercialization of IMBRUVICA® (ibrutinib). Dr. Lu holds a doctorate in organic chemistry from Purdue University in 1995.
Dr. Longphre has more than 20 years of biopharmaceutical industry experience in immunology, inflammation and respiratory therapeutic areas. Prior to joining Connect, Dr. Longphre was Director of Clinical Research at Novartis where she oversaw development of inhaled anti-inflammatory combination products to treat lung disease. Prior to that role, Dr. Longphre was a founding scientist at Aerovance, a spin-out of Bayer Biotechnology’s respiratory biologics portfolio, where her discovery research contributed to the understanding of the importance of IL-4 and IL-13 dysregulation in asthma and atopic dermatitis, and she directed studies of drug candidates that entered Phase 1-3 clinical trials for respiratory disease indications and atopic dermatitis. She was also a discovery scientist at Bristol-Myers Squibb in the department of Immunology, Inflammation and Pulmonary Disease and conducted respiratory inflammation research at the University of California San Francisco. Dr. Longphre is an inventor of nine issued patents for therapeutic entities and targets. She received her Ph.D. in Pulmonary Physiology Environmental Health Sciences at Johns Hopkins University and a M.A. and B.A. in Biology from University of North Carolina Greensboro.
Mr. McDade is Co-founder and Managing Partner of the Qiming US Healthcare Fund, a venture capital firm based in Seattle and formed in January 2017. Prior to Qiming, from April 2008 until his retirement in October 2016, Mr. McDade was EVP and Chief Operating Officer at UCB S.A., a Belgian biopharmaceutical company. From 2002 to 2007, Mr. McDade served as Chief Executive Officer and a member of the board of directors of PDL BioPharma, Inc., a biotechnology company. From 2000 to 2002, Mr. McDade was Chief Executive Officer of Signature BioScience, Inc., a drug discovery company. From 1994 to 2000, Mr. McDade served as Chief Operating Officer and a director of Corixa Corporation, a biopharmaceutical company he co-founded in Seattle. Prior to Corixa, Mr. McDade held various roles at Boehringer Mannheim (now part of Roche) and previously Sandoz (now part of Novartis). Mr. McDade chairs the board of directors of Aimmune Therapeutics (AIMT-nasdaq) and serves as a Trustee for the National Marine Sanctuary Foundation, a non-profit. Mr. McDade received a B.A. in History from Dartmouth College and an M.B.A. from the Harvard Business School.